The once consolidating orthopedic implant business is, if anything, going in the opposite direction, given the decisions this week by parents of two of the leading companies to create stand-alone companies of their orthopedic businesses. First, Bristol-Myers Squibb Co. confirmed what had been rumored for months: that it will spin off its Zimmer Inc. orthopedics business into a public company rather than sell the company to some other player [See Deal]. Earlier, Sulzer AG announced that it plans to spin off its medical device business, Sulzer Medica Ltd. , in response to pressure from a large investor who was concerned about the industrial giant's declining stock performance.
The motives for each decision, however, seem to have been different and largely financial—rather than market-driven. According to news reports,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?